Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphocyte

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: 1989 ND: 15867 AU: Monti-D, Cossarizza-A, Troiano-L, Arrigoni-Martelli-E, Franceschi-C. IN: Institute of General Pathology, University of Modena, 41100 Modena, Italy. TI: Immunomodulatory properties of L-acetylcarnitine on lymphocytes from young and old humans. SO: PROCEEDINGS OF THE WORKSHOP,POMEZIA,ROME,ITALY,13 SEPTEMBER 1988;IN: DE SIMONE C.,ARRIGONI-MARTELLI E."STRESS, IMMUNITY AND AGEING. A ROLE FOR ACETYL- L-CARNITINE", 1989, PAG.83-96 - ELSEVIER SCIENCE PUBLISHERS B.V.
    Active substance: ACETYL-L-CARNITINE
    Study summary document link (including results):
    View full study record
    Document reference: 46205
    Study title: Velazquez-A, Teran-M, Baez-A, Gutierrez-J, Rodriguez-R. Unidad de Genetica de la Nutricion, Instituto de Investigaciones Biomedicas UNAM, Mexico. Biotin supplementation affects lymphocyte carboxylases and plasma biotin in severe protein-energy malnutrition. The American journal of clinical nutrition, {Am-J-Clin-Nutr}, Feb 1995, vol. 61, no. 2, p. 385-91, ISSN: 0002-9165.Velazquez-A, Teran-M, Baez-A, Gutierrez-J, Rodriguez-R. Unidad de Genetica de la Nutricion, Instituto de Investigaciones Biomedicas UNAM, Mexico. Biotin supplementation affects lymphocyte carboxylases and plasma biotin in severe protein-energy malnutrition. The American journal of clinical nutrition, {Am-J-Clin-Nutr}, Feb 1995, vol. 61, no. 2, p. 385-91, ISSN: 0002-9165.
    Active substance: BIOTIN
    Study summary document link (including results):
    View full study record
    Document reference: 22619
    Study title: Analyse de metaphases de lymphocytes de sujets traites par le Bendazac-lysine
    Active substance: DAPIPRAZOLE
    Study summary document link (including results):
    View full study record
    Document reference: 25556
    Study title: Analyse de metaphases de lymphocytes de sujets traites par le Bendazac-lysine
    Active substance: DAPIPRAZOLE
    Study summary document link (including results):
    View full study record
    Document reference: 25557
    Study title: Pediatr Res. 2007 Feb;61(2):209-14. Cytogenetic damage in blood lymphocytes and exfoliated epithelial cells of children with inflammatory bowel disease. Holland N, Harmatz P, Golden D, Hubbard A, Wu YY, Bae J, Chen C, Huen K, Heyman MB.
    Active substance: FOLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28463
    Study title: Anlar B, Guven A, Kose G, Okur H, Kose O, Aydin OF, Kabakus N, Altunbasak S, Herguner O, Sonmez M, Serdaroglu A. J Neuroimmunol. 2005 Jun;163(1-2):195-8. Lymphocyte subsets, TNF alpha and interleukin-4 levels in treated and untreated subacute sclerosing panencephalitis patients.Anlar B, Guven A, Kose G, Okur H, Kose O, Aydin OF, Kabakus N, Altunbasak S, Herguner O, Sonmez M, Serdaroglu A. J Neuroimmunol. 2005 Jun;163(1-2):195-8. Lymphocyte subsets, TNF alpha and interleukin-4 levels in treated and untreated subacute sclerosing panencephalitis patients.
    Active substance: INOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 30068
    Study title: Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO / EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). - Bacigalupo A. et al - 2000 (Blood 95: 1931 - 1931) - Publication - Ref17 of Clinical Expert Report -
    Active substance: LENOGRASTIM
    Study summary document link (including results):
    View full study record
    Document reference: 31032
    Study title: Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.Clark G1, Walsh G, Deshpande P, Koffman G. Nephrol Dial Transplant. 2002 Jul;17(7):1304-9.
    Active substance: Azathioprine
    Study summary document link (including results):
    View full study record
    Document reference: 49255
    Study title: Litzman J, et al . 1999 Scripta Medca (BRNO) 72 (4) 115 -124. Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T lymphocyte immunodeficiency. Litzman J, et al . 1999 Scripta Medca (BRNO) 72 (4) 115 -124. Isoprinosine in the treatment of children with frequent respiratory tract infections and minor T lymphocyte immunodeficiency.
    Active substance: INOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 30140
    Study title: Cytogenetic analysis of peripheral blood lymphocytes after arteriography (exposure to x-rays and contrast medium)Popova L 2005. Radio/ Oncol 2005; 39(2): 153-8.
    Active substance: IODIXANOL
    Study summary document link (including results): 2011-09 GE Visipaque response List of published articles.doc
    View full study record
    Document reference: 48197
    Study title: Tekgul H, Tutuncuoglu S, Kutukculer N, Dizdarer G, Huseyinov A. J Child Neurol. 1999 Jul;14(7):418-21. Lymphocyte subsets and inflammatory mediators in patients with subacute sclerosing panencephalitis.Tekgul H, Tutuncuoglu S, Kutukculer N, Dizdarer G, Huseyinov A. J Child Neurol. 1999 Jul;14(7):418-21. Lymphocyte subsets and inflammatory mediators in patients with subacute sclerosing panencephalitis.
    Active substance: INOSINE
    Study summary document link (including results):
    View full study record
    Document reference: 30173
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:10:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA